Evaxion Biotech A/S announced on February 14, 2025, that Nasdaq confirmed the company is fully compliant with its listing requirements and has withdrawn the previous delisting determination. This resolution ensures Evaxion will remain listed on Nasdaq.
The company successfully restored its equity above the minimum requirement through recent capital market activities. This financial strengthening has also extended Evaxion’s cash runway until mid-2026.
Furthermore, the conversion of Evaxion’s European Investment Bank (EIB) loan to equity is still expected to be completed in the first quarter of 2025. This conversion is anticipated to further boost the company's equity position.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.